Welcome to our dedicated page for Progressive Care news (Ticker: RXMD), a resource for investors and traders seeking the latest updates and insights on Progressive Care stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Progressive Care's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Progressive Care's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Progressive Care Inc. (OTCQB: RXMD) reported its financial results for the year ending December 31, 2022, showing a 5% revenue increase to $40.6 million. Key highlights include a 7% rise in prescription revenue to $36.3 million and a $1.0 million increase in 340B contract revenue. However, gross profit margin decreased from 26% to 24%, primarily due to reduced COVID-19 testing revenue. The net loss expanded to $5.9 million, influenced by non-recurring expenses. The company successfully raised $5.4 million in capital and reduced convertible debt interest rates from 10% to 5%.